Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1361-1370 of 2916 for cancer

Edit search filters
  1. Highly Selective CDK7 Inhibitor Q901 In Selected Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Phase II, Multicenter Study Of The EZH2 Inhibitor Tazemetostat In Adult Subjects With INI1-Negative Tumors Or Relapsed/Refractory Synovial Sarcoma

    Jacksonville, FL

  3. A Study Of ASTX660 Alone Or Combined With ASTX727 In Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

    Rochester, MN

  4. Lenalidomide And Low-Dose Dexamethasone In Patients With Previously Treated Multiple Myeloma And Kidney Dysfunction

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. Study Of Iomab-B Prior To HCT Vs. Conventional Care In Older Subjects With Active, Relapsed Or Refractory AML

    Jacksonville, FL, Rochester, MN

  6. Study To Evaluate The Efficacy And Safety Of Lutathera In Patients With Grade 2 And Grade 3 Advanced GEP-NET

    Rochester, MN

  7. Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

    Rochester, MN

  8. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

  9. First In Human (FIH) Study Of REGN5459 In Patients With Relapsed Or Refractory Multiple Myeloma (MM)

    Rochester, MN

  10. Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer